In September 2024, we had a precious encounter with Professor Arieh Warshel, the chief scientist of MoMed Biotech, a member of the National Academy of Sciences of the United States and the winner of the 2013 Nobel Prize in Chemistry. Professor Warshel personally visited MoMed Biotech and had in-depth exchanges with the research and development team to understand the latest progress of research and development projects and gave highly professional guidance.

Recently, MoMed Biotech's R&D team announced the first batch of activity and animal experiment data for the breast cancer PROTAC pipeline. The initial results obtained from the research, which was designed using MoMed Biotech's MechGen multidimensional intelligent technology platform, indicate that the PROTAC protein degrader molecule CZ-501, which targets ER degradation, performs excellently in terms of both efficacy and safety, with its activity and other indicators reaching the best level in the industry.